Results 81 to 90 of about 4,421 (195)

Concentrated insulins: the new basal insulins

Therapeutics and Clinical Risk Management, 2016
Elizabeth M Lamos,1 Lisa M Younk,2 Stephen N Davis3 1Division of Endocrinology, Diabetes and Nutrition, 2Department of Medicine, University of Maryland School of Medicine, 3Department of Medicine, University of Maryland Medical Center, Baltimore, MD ...
Lamos EM, Younk LM, Davis SN
doaj  

Long-acting insulin allergy in a diabetic child

International Journal of Immunopathology and Pharmacology, 2017
Insulin allergy has been uncommon since the introduction of human recombinant insulin preparations; the prevalence is 2.4%. Insulin injection could elicit immediate reactions, which are usually induced by an IgE-mediated mechanism, within the first hour ...
Carla Mastrorilli, Laura Rizzuti, Antonina Marta Cangelosi, Brunella Iovane, Giovanni Chiari, Carlo Caffarelli   +5 more
doaj   +1 more source

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement

Indian Journal of Endocrinology and Metabolism, 2016
Insulin degludec/insulin aspart (IDegAsp) is a modern coformulation of ultra-long-acting basal insulin degludec, with rapid-acting insulin aspart. IDegAsp provides effective, safe, well-tolerated glycemic control, with a low risk of hypoglycemia while ...
Sanjay Kalra, Zafar A Latif, Abdurrahman Comlekci, Guillermo Gonzalez Galvez, Rached Malik, Md Faruque Pathan, Ajay Kumar   +6 more
doaj   +1 more source

[Basal insulin degludec (Tresiba®)].

, 2019
Insulin degludec (Tresiba®) is characterized by an original mode of prolonged and continuous insulin release after its subcutaneous injection. Thereby, it has a very long glucose-lowering effect, around 42 hours, and a better reproducibility from both a ...
Scheen, A.J., Mathieu, C.
core  

Basal insulin degludec (Tresiba(R))

, 2019
peer reviewedInsulin degludec (Tresiba(R)) is characterized by an original mode of prolonged and continuous insulin release after its subcutaneous injection.
Scheen, André, Mathieu, Chantal
core  

Effects of Switching from Degludec to Glargine U300 in Patients with Insulin-Dependent Type 1 Diabetes: A Retrospective Study

Medicina
Background and Objectives: Degludec (Deg) and glargine U300 (Gla-300) are insulin analogs with longer and smoother pharmacodynamic action than glargine U100 (Gla-100), a long-acting insulin that has been widely used for many years in type 1 and type 2 ...
Toshitaka Sawamura, Shigehiro Karashima, Azusa Ohbatake, Takuya Higashitani, Ai Ohmori, Kei Sawada, Rika Yamamoto, Mitsuhiro Kometani, Yuko Katsuda, Takashi Yoneda   +9 more
doaj   +1 more source

Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes & Metabolism
Introduction Once‐weekly basal insulin Fc (BIF) offers a promising alternative to daily basal insulin by reducing injection burden while maintaining glycaemic control.
Saaed Abunada, Sheela Bai, Usha Kumari, F. N. U. Nancy, Areeba Khan, Nikeeta Bai, F. N. U. Shevani, Anusha Bai, Shah Dev, Noshad Zain ul Abiddin, F. N. U. Umer, Abdul Manan, Sadia Habib Bhutto, Salih Abdella Yusuf   +13 more
doaj   +1 more source

Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy

, 2019
Aims: The costs associated with insulin therapy and diabetes-related complications represent a significant and growing economic burden for healthcare systems.
Michael L. Wolden (6692944), Jens Gundgaard (3608846), Steffen Haldrup (3996431), Annunziata Lapolla (4421137)   +3 more
core   +1 more source

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial [PDF]

, 2016
Achieving glycemic control remains a challenge for patients with type 2 diabetes, even with insulin therapy. To assess whether a fixed ratio of insulin degludec/liraglutide was noninferior to continued titration of insulin glargine in patients with ...
García-Hernández, Pedro, Buse, John B., Norwood, Paul, Lehmann, Lucine, Tarp-Johansen, Mads Jeppe, Manghi, Federico Perez, Lingvay, Ildiko   +6 more
core   +1 more source

Degludek: napjaink ideális bázisinzulinja? [Degludec: the ideal basal insulin of today]

, 2019
A degludek egy ultrahosszú hatású bázis-inzulinanalóg, amelyből a B30-as pozíciójú treonint eltávolították és a B29-es lizinhez egy 16 szénatomos zsírsavat kapcsoltak. Az injekció beadása után a degludek a subcutan térben oldékony multihexamereket képez.
Gerő, László
core   +1 more source